 To assess the safety of dasatinib BMS-354825 in subjects with Imatinib resistant or intolerant chronic myelogenous leukemia CML and Philadelphia chromosome positive Ph acute lymphoblastic leukemia ALL who are resistant or intolerant to treatment and will continue study drug after completing the previous Phase III study CA180031NCT00337454 